Labels for the aliskiren-containing drugs, Amturnide, Tekturna, Tekturna HCT, Tekamlo, and Valturna, are being updated to warn against the use of the drug with angiotensin receptor blockers (ARBs) or ACE inhibitors in patients with diabetes because of a risk of renal impairment, hypotension, and hyperkalemia.

Also being added is a warning to avoid the use of aliskiren with ARBs or ACE inhibitors in patients with moderate to severe renal impairment (GFR below 60 mL/min/1.73 m2) .

From the June 01, 2012 Issue of Renal and Urology News